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BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of visual loss among the elderly. A
key cell type involved in AMD, the retinal pigment epithelium, expresses a G proteinecoupled receptor that, in
response to its ligand, L-DOPA, up-regulates pigment epitheliaederived factor, while down-regulating vascular
endothelial growth factor. In this study we investigated the potential relationship between L-DOPA and AMD.
METHODS:We used retrospective analysis to compare the incidence of AMD between patients taking vs not
taking L-DOPA. We analyzed 2 separate cohorts of patients with extensive medical records from the
Marshﬁeld Clinic (approximately 17,000 and approximately 20,000) and the Truven MarketScan outpatient
and databases (approximately 87 million) patients. We used International Classiﬁcation of Diseases, 9th
Revision codes to identify AMD diagnoses and L-DOPA prescriptions to determine the relative risk of
developing AMD and age of onset with or without an L-DOPA prescription.
RESULTS: In the retrospective analysis of patients without an L-DOPA prescription, AMD age of onset was
71.2, 71.3, and 71.3 in 3 independent retrospective cohorts. Age-related macular degeneration occurred
signiﬁcantly later in patients with an L-DOPA prescription, 79.4 in all cohorts. The odds ratio of developing
AMD was also signiﬁcantly negatively correlated by L-DOPA (odds ratio 0.78; conﬁdence interval, 0.76-
0.80; P <.001). Similar results were observed for neovascular AMD (P <.001).
CONCLUSIONS: Exogenous L-DOPA was protective against AMD. L-DOPA is normally produced in pigmented
tissues, such as the retinal pigment epithelium, as a byproduct of melanin synthesis by tyrosinase. GPR143 is the only
knownL-DOPAreceptor; it is thereforeplausible thatGPR143maybea fruitful target tocombat thisdevastatingdisease.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016)
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Brilliant et al L-DOPA and Age-related Macular Degeneration 293Developing a new drug costs more than $2 billion and takes
13.5 years from discovery to market. Drug repositioning
does not require anywhere near these costs and has been
successfully used for more than a dozen drugs.1 Electronic
medical records (EMRs) offer a powerful tool to examine the
effects of a drug on conditions for which it was not originallyCLINICAL SIGNIFICANCE
Patients prescribed L-DOPA are less
likely to develop age-related macular
degeneration (AMD).
In patients taking L-DOPA who did
develop AMD, the age of onset was
signiﬁcantly delayed.
L-DOPAmay both prevent and delay AMD
in aged patients.prescribed.2 Indeed, long-term
EMRs can be mined for retro-
spective data to develop a “virtual
prospective” drug repurposing
study. Here we use EMR analysis
to determine whether L-DOPA, a
drug used for movement disorders,
is a candidate for treatment of an
unrelated disease, age-related
macular degeneration (AMD).
Age-related macular degenera-
tion is the leading cause of blind-
ness in developed nations,3-6 even
accounting for 10% of blindness in
Sudan.7 Despite years of intensive
research efforts, we do not know the cause of AMD. Patients
with AMD typically experience a gradual loss of central
vision over years. Most patients develop geographic atrophy,
a progressive loss of the region of highest visual acuity, the
macula. When this atrophy involves the center of the macula,
visual acuity drops precipitously. The other form of AMD
includes the development of abnormal blood vessels, or
neovascularization, leading to “wet” or “exudative” AMD.
These abnormal blood vessels, if left untreated, result in
progressive leakage, bleeding, and irreversible scarring of the
macula.8 Wet AMD tends to develop suddenly and progress
rapidly, resulting in catastrophic vision loss.9-15 Although wet
AMD only occurs in 10%-15% of AMD cases, it is respon-
sible for most blindness due to AMD.16
The impact of AMD on Americans is staggering. Age-
related macular degeneration affects patients of all ethnic-
ities, but vision loss due to AMD is most common among
Caucasians and is approximately 5-fold less common
among those of African descent, with intermediate risk in
Hispanic and Asian populations.4,6,17 Approximately 9
million people in the United States have moderate to severe
AMD, and this is projected to increase to more than 16
million by the year 2020.12,18 Approximately 1.75 million
of these people have vision loss or immediate vision-
threatening disease (wet AMD or geographic atrophy).18
The cost associated with AMD will only increase as the
number of people over the age of 65 years increases. For those
patients with vision loss due to AMD through geographic at-
rophy, there is no treatment at all, only vitamin supplements
that may slow vision loss.19,20 Recent progress in the use of
agents that inhibit vascular endothelial growth factor (VEGF)
has signiﬁcantly improved the outcomes of patients who
developwet AMD.21-24 These treatments have been successful
in preserving vision, but this comes at a cost of signiﬁcantdiscomfort, inconvenience, and expense. The most successful
treatment involves repeated injections of VEGF inhibitors
directly into the eye. Although successful, these drugs can be
incredibly expensive.25 The cost of this treatment strategy in
2010 through Medicare Part B was just under $2 billion.26
We have previously discovered a G proteinecoupled re-
ceptor that binds to and is activated
by L-DOPA.27 This receptor,
GPR143, is expressed in the retinal
pigment epithelium, a primary
support tissue for the neurosensory
retina. Further, we have shown that
GPR143 controls trophic factor
release by the retinal pigment
epithelium,27,28 such that GPR143
signaling may protect from AMD.
Herein we test this novel hypothe-
sis to investigate whether L-DOPA
may be repositioned as an AMD
preventative drug, using EMRs in a
virtual prospective clinical trial.METHODS
We used International Classiﬁcation of Diseases, 9th Revi-
sion (ICD-9) codes 362.50, 362.51, 362.52, and 362.57 to
capture all AMD diagnoses from each database. We used
prescription history of L-DOPA, rather than Parkinson’s
disease diagnosis (PD: ICD-9 332), because many with
Parkinson’s disease do not take L-DOPA, and individuals
without Parkinson’s disease are prescribed L-DOPA for
other movement disorders. Because our real question related
to L-DOPA and AMD, regardless of why they were pre-
scribed L-DOPA, this creates an unbiased observation.
Statistical analysis included t test analysis and bino-
mial testing for the Marshﬁeld Clinic Cohort (equation
below) to examine the population distribution. For the
Truvan MarketScan Cohort we limited our analysis to
those with a record of Ophthalmology, for any reason
(15,215,458 individuals). This allows for selecting pa-
tients with access to ophthalmologists or other healthcare
providers diagnosing ophthalmic conditions without
affecting the potential relationship between L-DOPA use
and AMD. The prevalence of AMD in this selected
population was 4.5%, indicating that AMD was not
overrepresented by including individuals who had an
ophthalmology history.
For comparisons, using SPSS (version 22; SPSS Inc,
Chicago, Ill), an independent-samples t test was used to
compare the age difference between the groups, and multi-
nomial regression analysis was used to control for potential
confounding variables (age and gender) and to evaluate the
association between L-DOPA use and diagnosis of AMD by
calculating odds ratios (ORs), 95% conﬁdence intervals
(CIs), and P-values.
Figure 1 Age distribution of subjects in the Marshﬁeld
Clinic Cohorts. The data summarize the age distributions for
a ﬁrst prescription (Rx) for L-DOPA (n ¼ 314), diagnosis
(Dx) of age-related macular degeneration (AMD) (n ¼ 1795),
or a record of L-DOPA before a diagnosis of AMD (n ¼ 10).
Errors bars represent the 95% conﬁdence interval. *P<.01 by
t test analysis.
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Marshﬁeld Clinic Cohorts
To determine the possible relationship between L-DOPA
and AMD, we examined clinical data from the Marshﬁeld
Clinic’s Personalized Medicine Research Project (PMRP)
(N ¼ approximately 20,000),29 plus an additional non-
overlapping group of approximately 17,000 patients with
long-term nearly complete electronic health records in the
Marshﬁeld Epidemiologic Study Area.30 Institutional re-
view board approval was obtained. In the PMRP cohort,
AMD was present in 5.7% of the subjects (n ¼ 1142), and
Parkinson’s disease (ICD-9 332) was present in 0.85% of
the subjects (n ¼ 170). However, AMD and Parkinson’s
disease were found together in 0.21% of the subjects
(n ¼ 43), 4 times the expected rate if they are independent
variables, not unexpected because both AMD and Parkin-
son’s disease are disorders of aging and may even share
some common etiology. However, the etiologies of the 2
diseases have not previously been shown to intersect, and
they do not share any known risk factors. In fact, one of the
main risk factors for AMD, smoking,31 may protect from
Parkinson’s disease.32,33
Because we are primarily interested in determining the
effect of L-DOPA on AMD and because only 67% of the
Parkinson’s disease patients in PMRP have been given L-
DOPA (and other patients are prescribed L-DOPA), subse-
quent analyses included all patients taking L-DOPA (1.1%
of PMRP, n ¼ 229) with or without Parkinson’s disease. We
found that an AMD diagnosis (Dx) and L-DOPA prescrip-
tion (Rx) also occurred together in the EMR 3 times more
frequently than expected (in 0.2% of subjects, n ¼ 39), even
after stratifying for age. To control for this, we examined the
39 patients with both an AMD Dx and L-DOPA Rx in their
EMR. Because the average age of L-DOPA Rx is 67.1
years, and the average age of onset of AMD in the PMRP
cohort is 71.2 years, we would expect a bias that L-DOPA
Rx appears in the EMR earlier then AMD Dx in patients
with both in their EMR. However, the opposite trend was
found. Of the 39 patients in PMRP with both AMD and L-
DOPA in their EMR, 30 received L-DOPA after the AMD
diagnosis; 4 received L-DOPA in the same year; and 5
received L-DOPA before the AMD diagnosis. This same
trend was noted within the major age brackets: ages 65-70
years: 9 LDOPA after AMD, 1 L-DOPA before AMD; ages
70-75 years: 10 L-DOPA after AMD, 1 same year; ages 75-
80 years: 4 L-DOPA after AMD, 2 L-DOPA before AMD, 2
same year; ages 80-85 years: 3 LDOPA after AMD, 1 L-
DOPA before AMD. We also examined an independent
patient cohort, a subset of the Marshﬁeld Epidemiologic
Study Area (approximately 100,000 people), consisting of
approximately 17,500 individuals with more complete
EMRs. The same trends were noted in the 20 patients in this
cohort with both AMD and L-DOPA in their EMR: 14
received L-DOPA after the AMD diagnosis; 1 received L-
DOPA in the same year; and 5 received L-DOPA before the
AMD diagnosis. Figure 1 summarizes the combined datafor patients from both cohorts, PMRP and the Marshﬁeld
Epidemiologic Study Area subset (n ¼ approximately
37,500). Thus, our study shows that AMD and
Parkinson’s disease (or L-DOPA Rx) occur more
frequently together than if they were independent, even
after stratifying for age. As illustrated in Figure 1, for our
combined cohorts, the average L-DOPA Rx age is 67.2
years, 4 years younger than the average AMD Dx age
(71.3 years), similar to other studies. Just as in the PMRP
subset, the expectation is that we should see more
individuals with an L-DOPA Rx before an AMD Dx in
individuals who have AMD and have taken L-DOPA at
any time. However, again the opposite pattern is seen: the
vast majority have taken L-DOPA only after an AMD Dx
(Z score 4.627; P <.001), implying that L-DOPA is
protective against AMD. Most intriguingly, shown in
Figure 1 and summarized in Table 1, the AMD Dx age is
signiﬁcantly skewed in the 10 people who had an L-
DOPA Rx before the AMD Dx (79.3) compared with the
44 people who had L-DOPA after the AMD Dx (71.3),
demonstrating that the AMD Dx was signiﬁcantly delayed
in people taking L-DOPA before getting AMD (t test:
3.567; P <.01).
Our age distribution of AMD Dx and L-DOPA Rx ﬁts
the known national pattern,34,35 and so we expect to see
more individuals with an L-DOPA Rx before an AMD Dx.
Table 1 Age of Onset Summary
Study
Group Individuals
Age of
L-DOPA
Prescription (y)
Age (y) of
AMD Without
L-DOPA (n)
Age (y) of
AMD With
L-DOPA (n)
Age (y) of
Neovascular
AMD Without
L-DOPA
Age (y) of
Neovascular
AMD With
L-DOPA
Age (y) of
AMD With
Dopaminergic
Agonists
PMRP 20,000 67.1 71.2 (1,142) 79.3 (10)
MESA 17,500 67.2 71.3
TruvanMarket Scan 15,215,458 68 71.4 (679,574) 79.3 (12,387) 75.8 80.8 73.9
AMD ¼ age-related macular degeneration; MESA ¼ Marshﬁeld Epidemiologic Study Area; PMRP ¼ Marshﬁeld Clinic’s Personalized Medicine Research
Project.
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vative null model assumption in which only half of L-
DOPA Rx cases will be before AMD Dx. We also conser-
vatively assumed that only 44 of the 54 individuals had the
L-DOPA Rx after the AMD Dx (ie: we categorized the 7
individuals for whom the L-DOPA Rx date was effectively
indistinguishable from the AMD Dx). The resulting con-
servative P-value for observing 44 or more individuals from
the 54 total under these assumptions was 1.7E-06, which is
highly signiﬁcant. We conclude that because the actual P-
value of the data is more highly signiﬁcant than the con-
servative one calculated, these data offer compelling evi-
dence that there is substantial skewing of AMD Dx dates to
later than the L-DOPA Rx dates than one would expect.

1
2
54 X54
i¼ 44
54!
i!ð54 iÞ! ¼ 1:69E  06 (1)
Equation 1 Binomial test equation used to determine
signiﬁcance of age distribution for Marshﬁeld Clinic
datasets.Truven MarketScan cohort
To further examine the possible protective role for DOPA
on AMD, we performed a similar retrospective analysis
using the Truven MarketScan outpatient databases from the
years 2007-2011 (Truven Health Analytics). These are the
largest insurance claim-based proprietary databases in the
United States, containing medical insurance claim records of
more than 87 million unique individuals. The de-identiﬁed
and anonymized data provided by MarketScan databases
include demographic and medical diagnosis information.
The Outpatient Prescription Drug databases provide data
regarding the medications used (both generic and brand) by
each patient (in the form of National Drug Codes) and the
dates in which medications were dispensed to patients.
Figure 2 summarizes our statistical analysis of the
MarketScan cohort. In the subset of patients with a record
of ophthalmology-related diagnosis, we found that the
mean age at ﬁrst recorded AMD diagnosis in patients not
treated with L-DOPA (n ¼ 679,574) was 71.4 years, in
agreement with both cohorts from Marshﬁeld Clinic and in
agreement with AMD incidence statistics.34 Thus, althoughwe do not have complete medical records, this cross-
sectional cohort matches other population-based AMD
incident characteristics. We also examined the mean age of
L-DOPA prescription in all of MarkestScan databases to
determine whether that matched population-based statistics
and the Marshﬁeld databases, and found the average age of
L-DOPA prescription was 68 years, again similar to the
Marshﬁeld Clinic cohort and national averages. These data
are summarized in Table 1.
Having veriﬁed that both AMD age of onset and L-
DOPA prescription ages match expectations, we investi-
gated the intersection of those populations. As illustrated in
Figure 2, the mean age of ﬁrst AMD diagnosis in patients
with an L-DOPA prescription record was 79.3 years (n ¼
12,387), and this was signiﬁcantly later than in individuals
without an L-DOPA prescription, 71.4 years (P <.001).
Using multinomial logistic regression, we found that after
controlling for age and gender, patients with a prescription
history of L-DOPA were signiﬁcantly less likely to have a
diagnosis of AMD (OR 0.78; CI, 0.76-0.80; P <.001).
Importantly, this ﬁnding was also carried through with
diagnoses of neovascular AMD (ICD-9 362.52). After
controlling for age and gender, and excluding patients
with a record of neovascular AMD before an L-DOPA
prescription history, we found that age of onset of wet
AMD without L-DOPA was 75.8 years, whereas
neovascular AMD onset in those with an L-DOPA
prescription history was 80.8 years, and this difference
was signiﬁcant, P <.001. Further, the OR suggests that
patients with a record of L-DOPA were signiﬁcantly less
likely to have a diagnosis of neovascular AMD (OR 0.65;
95% CI, 0.65-0.69; P <.001). Although we suspect that
the positive trophic environment developed by increasing
retinal pigment epithelium secretion of pigment
epithelium-derived factor (PEDF) may account for protec-
tion from AMD via GPR143 signaling, a corresponding
decrease in VEGF secretion from the retinal pigment
epithelium is also possible.28 The combined effect of
increased PEDF, a potent antiangiogenesis factor,36-38 and
decreased secretion of VEGF may act together to reduce
neovascular AMD.
We also examined whether this effect was speciﬁc for L-
DOPA by testing for a potential relationship between pa-
tients taking other movement disorder drugs. These drugs
Figure 2 Data from the Truven MarketScan database illustrates that L-DOPA both delays age-related
macular degeneration (AMD) onset and reduces the risk of developing AMD. (A) Data represent the age
of AMD onset in several groups, with error bars representing the 95% conﬁdence interval. The AMD
group represents our control individuals that had no record of movement disorder prescription history.
The L-DOPA AMD group represents all individuals with an International Classiﬁcation of Diseases, 9th
Revision (ICD-9) code for AMD that also had a prescription history for L-DOPA. Neovascular (NV)
AMD represents individuals with the speciﬁc ICD-9 code 362.52 but no history of L-DOPA pre-
scriptions. The L-DOPA and NV AMD group is similar except that the individuals had a history of L-
DOPA prescriptions. The dopamine agonist group represents individuals who had a prescription history
for various movement disorder drugs, largely dopamine agonists. All groups were signiﬁcantly different
from the AMD control. *P <.001. (B) Odds ratio analysis to determine whether the drugs alter the
probability of developing AMD. All values below 1, representing the control, AMD with no L-DOPA or
movement disorder prescription history, indicating a reduction in the probability risk of developing
AMD, either in general or speciﬁcally NV AMD. Each reduction in risk was signiﬁcant. *P <.001.
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dopamine receptor. As shown in Figure 2, we found a small
but signiﬁcant delay in AMD onset in this group, which
developed AMD at 73.9 years (CI, 73.73-74.10 years; P
<.05). The OR for this group is 0.71 (CI, 0.70-0.73; P
<.001). When compared with the age of onset with no
drug (71.34 years) or L-DOPA (79.26 years), this was
signiﬁcantly different than both (P <.05). In our previous
studies of GPR143, we showed that dopamine and L-
DOPA, closely related molecules, compete for the same
GPR143 binding site,27 suggesting that dopamine receptor
agonists developed for movement disorders may cross-react
with GPR143. However, it is also possible that other
dopamine receptors are participating in the effect we
observed. We also examined this in the Marshﬁeld data-
bases but found no effect on AMD onset or OR for any
other movement disorder therapies.DISCUSSION
In this retrospective study of 3 independent cohorts, we
show for the ﬁrst time that, of patients with a history of bothAMD and L-DOPA use, most received L-DOPA after an
AMD diagnosis, in contrast to the expected opposite trend
given that the mean age of L-DOPA prescription is years
earlier than AMD onset. Furthermore, those who went on to
have AMD were diagnosed with AMD at a signiﬁcantly
later age than those who had no record of taking L-DOPA.
These results were the same for both dry AMD and neo-
vascular AMD. These data strongly support a protective role
for L-DOPA in AMD pathogenesis. Our experimental
design does not allow us to speciﬁcally assess the mecha-
nism of action of L-DOPA on AMD incidence. GPR143 is
the only known receptor for L-DOPA,27,28,39 and signaling
through GPR143 simultaneously increases PEDF secretion
while decreasing VEGF, providing a plausible biological
explanation for the ameliorating effect of L-DOPA on the
retina. Normal aging in the retina includes both reduced
pigmentation,40,41 the source of L-DOPA, and retinal
PEDF.42 Our results may also explain the racial differences
in AMD frequency and suggest that pigmentation, a surro-
gate for GPR143 activity, may be protective from AMD.
Pigment epithelium-derived factor levels are signiﬁcantly
lower in vitreous and Bruch’s membrane of eyes with
Brilliant et al L-DOPA and Age-related Macular Degeneration 297neovascular AMD,43-45 further suggesting an imbalance
between retinal pigment epithelium secretion of PEDF and
VEGF as part of AMD pathology.45-47 Importantly, our data
suggest that GPR143 signaling, a component of both
pigmentation and PEDF/VEGF pathways, could be manip-
ulated pharmaceutically to prevent or delay AMD patho-
genesis. Finally, the drug to manipulate GPR143 signaling
exists, has been used by millions for 50 years, is safe, and is
available as a low-cost generic. Our data indicate prospec-
tive clinical trials to determine whether L-DOPA can pre-
vent AMD are warranted.ACKNOWLEDGMENTS
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